Exelixis, Inc. (Nasdaq: EXEL) has announced the results of a subgroup analysis from the CABINET phase 3 pivotal trial evaluating the efficacy of CABOMETYX (cabozantinib) against a placebo in patients with advanced neuroendocrine tumors (NET) originating in the lungs and thymus. The findings are scheduled to be presented during the Monday Poster Session: Neuroendocrine Tumours at the 2025 European Society for Medical Oncology Congress (ESMO), set to take place on October 20, 2025, from 12:00 to 12:30 PM.
The CABINET trial was designed to ascertain the therapeutic benefits of CABOMETYX in a cohort of patients who had previously received treatment for advanced NETs. Specifically, this recent analysis focuses on subgroups of individuals based on distinct variables such as tumour origin, treatment history, and other demographic factors.
Preliminary findings suggest that CABOMETYX may provide significant clinical advantages in extending progression-free survival and improving overall response rates compared to placebo, although comprehensive data and statistical analyses are expected to be fully disclosed during the conference presentation.
In a broader context, this development comes amidst a growing interest in targeted therapies for neuroendocrine tumours, a group of rare malignancies characterised by their neuroendocrine cell origin and varied clinical behaviour. The outcomes from this study could significantly influence treatment paradigms and therapeutic decisions in managing advanced lung and thymic NETs.
As of the latest reports, Exelixis Inc. has 284,393,000 shares outstanding, with a current stock price of $39.25. The implications of the CABINET trial’s findings may not only impact clinical practice but could also affect investor sentiment and the company’s market performance as developments unfold.
The presentation at ESMO 2025 is expected to attract considerable attention from oncologists and healthcare professionals involved in the treatment of neuroendocrine tumours, aiming to evaluate the potential of CABOMETYX as an essential therapeutic option in the evolving landscape of cancer treatment.This article provides an overview of key findings and implications from the CABINET phase 3 trial subsidiary analysis, which are pivotal for both clinical practice and future research in neuroendocrine tumours.’
Comments